185 research outputs found

    The impact of the time interval from diagnosis to radical prostatectomy on oncological outcomes in high-risk prostate cancer

    Get PDF
    Introduction. To date, the impact of the time interval from diagnostic prostate biopsy to radical prostatectomy on treatment outcomes remains a topical issue.Objective. To evaluate the effect of the timespan from diagnosis to radical treatment of prostate cancer (PCa) patients on tumor morphology and long-term oncological outcomes.Materials and methods. A retrospective analysis of the results of treatment of patients with high-risk PCa who underwent radical prostatectomy with extended lymphadenectomy from 2001 to 2019 in three St. Petersburg clinics was performed. The influence of the time interval from prostate biopsy to radical treatment on long-term outcomes was assessed.Results. An increase in the time interval before surgical treatment over three months did not affect the tumor morphology. Five-year biochemical relapse-free survival was 79.7%, 67.8% and 52.5% among patients with time interval from biopsy to surgical treatment less than 30 days, 30 – 90 days and more than 90 days, respectively. The time interval prior to radical treatment did not have any effect on overall and cancer-specific survival.Conclusion. The time interval from prostate biopsy to surgical intervention, not exceeding 3 months, is the most favorable with respect to long-term outcomes

    Polymorphism of ITS sequences in 35S rRNA genes in Elymus dahuricus aggregate species: two cryptic species?

    Get PDF
    Nuclear ribosomal internal transcribed spacer (ITS) sequences were sequenced for 23 species and subspecies of Elymus sensu lato collected in Russia. The Neighbor-Net analysis of ITS sequences suggested that there are four ribotypes called Core Northern St-rDNA, Core Southern St-rDNA, Northern dahuricus St-rDNA and Southern dahuricus St-rDNA. The Core Southern variant of St-rDNA is closely related to rDNA of diploid Pseudoroegneria stipifolia (PIΒ 313960) and P.Β spicata (PI 547161). The Core Northern St-rDNA is closely related to rDNA of P. cognata (PI 531720), a diploid species of Kyrgyzstan carrying StY variant of the St genome. The Core Northern St-rDNA is widespread among the Elymus species of Siberia and the Far East, including Yakutia and Chukotka. The Core Southern St-ribotype is typical of southern Elymus and Pseudoroegneria of the South Caucasus, Primorye, Pakistan, and South Korea. The Northern dahuricus St-ribotype and Southern dahuricus St-ribotype are derivatives of the Core Northern and Core Southern St-ribotypes, correspondingly. Both of them were found in all four studied species of the E. dahuricus aggregate: E. dahuricus Turcz. ex Griseb., E. franchetii Kitag., E. excelsus Turcz. ex Griseb. and Himalayan E. tangutorum (Nevski) Hand.-Mazz. In other words, there are at least two population groups (two races) of the Elymus dahuricus aggregate species that consistently differ in their ITS-sequences in Siberia, the Far East and Northern China. Each contains all morphological forms, which taxonomists now attribute either to different species of E. dahuricus aggr. (E. dahuricus sensu stricto, E. franchetii, E. tangutorum, E. excelsus) or subspecies of Campeiostachys dahurica (Turcz. ex Griseb.) B.R. Baum, J.L. Yang et C.C. Yen. At the moment it is unknown if there are any morphological differences between plants carrying either Northern or Southern dahuricus rDNA. Probably, they are cryptic species, but it is certain that if differences in morphology between the two races exist, they are not associated with signs that are now considered taxonomically significant and are used to separate E. dahuricus s. s., E. franchetii, E. tangutorum, and E. excelsus

    Effect of taxanes on the miR-106 and miR-200c expression in prostate cancer cells in vivo and in vitro

    Get PDF
    Introduction. A combination of antiandrogen and cytostatic drugs was justified in the neoadjuvant therapy of patients with high-risk prostate cancer (HiRPCa) in some clinical trials. The effectiveness of such therapy in each individual case depends on the sensitivity of cancer cells to the applied drugs. It makes possible the development of the new technologies to personalize therapeutic approach. MicroRNAs (miRNAs) are a class of regulatory molecules whose expression is altered in PCa cells and can be associated with the sensitivity/resistance of cancer cells to specific cytostatics, for instance, taxanes.Objective. To identify the potential-marker miRNAs of PCa cells sensitivity to taxanes.Materials and methods. Samples of PCa tissue (n. 56) obtained from patients underwent neo-adjuvant therapy (antiandrogen and taxanes) and radical prostatectomy; PCa cell lines (PC-3, DU-145, LNCap). Total RNAs isolation was carried out using miRNeasy FFPE Kit, LRU-100-50; miRCURY LNA miRNA Focus PCR Panel, All-MIR kits were used for semi-quantitative analysis of potentially marker microRNA molecules using sequential reverse transcription and PCR.Results. The effect of taxanes on PCa cells is associated with up-regulation of miR-106b expression and down-regulation of miR-200c expression in both in vivo and in vitro conditions.Conclusion. MiR-106b and miR-200c miRNAs are involved in the response of PCa cells to taxanes, and therapeutic modification of these molecules in PCa cells may present a potential strategy to increase their sensitivity to taxane-containing therapy. Appropriate innovative technology may be in demand in the treatment of HiRPCa-patients

    ΠŸΡ€ΠΎΠ³Ρ€Π°ΠΌΠΌΠ° Ρ€Π°Π½Π½Π΅Π³ΠΎ восстановлСния ΠΏΡ€ΠΈ Ρ€Π°Π΄ΠΈΠΊΠ°Π»ΡŒΠ½ΠΎΠΌ хирургичСском Π»Π΅Ρ‡Π΅Π½ΠΈΠΈ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… Ρ€Π°ΠΊΠΎΠΌ ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹: ΠΎΠΏΡ‹Ρ‚ спСциализированного стационара

    Get PDF
    Background. Currently, there are sufficient data on the favorable role of fast track program on the course of postoperative period. Nevertheless, the role of these protocols being already included in the standards of the surgical treatment of many cancers is not clear to date in oncourology in general and in the prostate cancer (PC).Objective: to determine the effect of fast track program elements for the results of treatment in patients after radical prostatectomy.Materials and methods. 86 radical minimally invasive (laparoscopic or endoscopic extraperitoneal) prostatectomies were performed for prostate cancer in the period from May 2015 to February 2016 in the Oncological Research Institute named after N.N. Petrov. Patients were divided into 2 groups: in patients of the 1st (n = 44) group included those with traditional surgical management fast track elements were not used at all or were used partly; in the 2nd group (n = 42) these elements were used in a whole volume. We have assessed an influence of fast track elements on the frequency of perioperative and early postoperative complications, operative time, duration of the hospitalization and duration of the stay in intensive care unit, frequency of the repeated surgical interventions, and frequency of the repeated hospitalizations within 30 days of the postoperative period.Results. The presence and the absence of preoperative preparation did not affect an incidence of intraoperative complications. Intraoperative blood loss did not lead to blood transfusions. There were no significant differences in the incidence of 30-day complications between groups. WhenΒ evaluating postoperative parameters there was difference between 1st and 2nd groups in the pelvis drainage (3.3 and 0.9 days, respectively, p = 0.002), an average duration of catheterization (11.2 and 5.2 days, respectively, p = 0.0003) and duration of hospitalization (15.1 and 6.5 days, respectively, p = 0.0008).Conclusion. Application of fast track program of perioperative management of patients with prostate cancer does not affect the frequency of intraand postoperative complications, but economically it is potentially more feasible, primarily by reducing the term of the patient stay in hospital.Π’Π²Π΅Π΄Π΅Π½ΠΈΠ΅. Π’ настоящСС врСмя сущСствуСт достаточно Π΄Π°Π½Π½Ρ‹Ρ… ΠΎ благоприятной Ρ€ΠΎΠ»ΠΈ ΠΏΡ€ΠΎΠ³Ρ€Π°ΠΌΠΌΡ‹ Ρ€Π°Π½Π½Π΅Π³ΠΎ восстановлСния (fast track) Π½Π° Ρ‚Π΅Ρ‡Π΅Π½ΠΈΠ΅ послСопСрационного ΠΏΠ΅Ρ€ΠΈΠΎΠ΄Π°. Π’Π΅ΠΌ Π½Π΅ ΠΌΠ΅Π½Π΅Π΅ Ρ€ΠΎΠ»ΡŒ этих ΠΏΡ€ΠΎΡ‚ΠΎΠΊΠΎΠ»ΠΎΠ², ΡƒΠΆΠ΅ Π²ΠΊΠ»ΡŽΡ‡Π΅Π½Π½Ρ‹Ρ… Π² стандарты ΠΏΡ€ΠΈ хирургичСском Π»Π΅Ρ‡Π΅Π½ΠΈΠΈ ΠΌΠ½ΠΎΠ³ΠΈΡ… онкологичСских Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ, Π½Π° сСгодняшний дСнь Π² ΠΎΠ½ΠΊΠΎΡƒΡ€ΠΎΠ»ΠΎΠ³ΠΈΠΈ Π² Ρ†Π΅Π»ΠΎΠΌ ΠΈ ΠΏΡ€ΠΈ Ρ€Π°ΠΊΠ΅ ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹ (Π ΠŸΠ–) Π² частности Π½Π΅ ясна.ЦСль исслСдования – ΠΎΠΏΡ€Π΅Π΄Π΅Π»ΠΈΡ‚ΡŒ влияниС элСмСнтов ΠΏΡ€ΠΎΠ³Ρ€Π°ΠΌΠΌΡ‹ fast track Π½Π° Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ лСчСния Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² послС Ρ€Π°Π΄ΠΈΠΊΠ°Π»ΡŒΠ½ΠΎΠΉ простатэктомии.ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹ ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. Π’ ΠΏΠ΅Ρ€ΠΈΠΎΠ΄ с мая 2015 Π³. ΠΏΠΎ Ρ„Π΅Π²Ρ€Π°Π»ΡŒ 2016 Π³. Π² НИИ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈΠΌ. Н.Н. ΠŸΠ΅Ρ‚Ρ€ΠΎΠ²Π° ΠΏΡ€ΠΎΠ²Π΅Π΄Π΅Π½ΠΎ 86 Ρ€Π°Π΄ΠΈΠΊΠ°Π»ΡŒΠ½Ρ‹Ρ… минимально ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½Ρ‹Ρ… (лапароскопичСских ΠΈΠ»ΠΈ Π²Π½Π΅Π±Ρ€ΡŽΡˆΠΈΠ½Π½Ρ‹Ρ… эндоскопичСских) простатэктомий ΠΏΠΎ ΠΏΠΎΠ²ΠΎΠ΄Ρƒ Π ΠŸΠ–. Π‘ΠΎΠ»ΡŒΠ½Ρ‹Π΅ Π±Ρ‹Π»ΠΈ Ρ€Π°Π·Π΄Π΅Π»Π΅Π½Ρ‹ Π½Π° 2 Π³Ρ€ΡƒΠΏΠΏΡ‹: Π² 1-ΠΉ Π³Ρ€ΡƒΠΏΠΏΠ΅ (n = 44) Ρ‚Ρ€Π°Π΄ΠΈΡ†ΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ хирургичСского вСдСния элСмСнты fast track Π½Π΅ примСняли совсСм ΠΈΠ»ΠΈ использовали частично; Π²ΠΎ 2-ΠΉ (n = 42) – Π² ΠΏΠΎΠ»Π½ΠΎΠΌ объСмС. ΠžΡ†Π΅Π½ΠΈΠ²Π°Π»ΠΈ влияниС выполнСния ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΠΉ fast track Π½Π° частоту ΠΈΠ½Ρ‚Ρ€Π°ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΎΠ½Π½Ρ‹Ρ… ΠΈ Ρ€Π°Π½Π½ΠΈΡ… послСопСрационных ослоТнСний, Π΄Π»ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΈ, сроки госпитализации ΠΈ нахоТдСния Π² ΠΎΡ‚Π΄Π΅Π»Π΅- Π½ΠΈΠΈ Ρ€Π΅Π°Π½ΠΈΠΌΠ°Ρ†ΠΈΠΈ ΠΈ интСнсивной Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ, частоту ΠΏΠΎΠ²Ρ‚ΠΎΡ€Π½Ρ‹Ρ… хирургичСских Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π², Π° Ρ‚Π°ΠΊΠΆΠ΅ ΠΏΠΎΠ²Ρ‚ΠΎΡ€Π½Ρ‹Ρ… госпитализаций Π² Ρ‚Π΅Ρ‡Π΅Π½ΠΈΠ΅ 30 Π΄Π½Π΅ΠΉ послСопСрационного ΠΏΠ΅Ρ€ΠΈΠΎΠ΄Π°.Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. НаличиС ΠΈ отсутствиС ΠΏΡ€Π΅Π΄ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΎΠ½Π½ΠΎΠΉ ΠΏΠΎΠ΄Π³ΠΎΡ‚ΠΎΠ²ΠΊΠΈ Π½Π΅ повлияли Π½Π° частоту развития ΠΈΠ½Ρ‚Ρ€Π°ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΎΠ½Π½Ρ‹Ρ… ослоТнСний. Π˜Π½Ρ‚Ρ€Π°ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΎΠ½Π½Π°Ρ кровопотСря Π½Π΅ ΠΏΡ€ΠΈΠ²Π΅Π»Π° ΠΊ нСобходимости выполнСния гСмотрансфузий. ДостовСрных Ρ€Π°Π·Π»ΠΈΡ‡ΠΈΠΉ Π² частотС развития 30-Π΄Π½Π΅Π²Π½Ρ‹Ρ… ослоТнСний ΠΌΠ΅ΠΆΠ΄Ρƒ Π³Ρ€ΡƒΠΏΠΏΠ°ΠΌΠΈ Π½Π΅ наблюдали. ΠŸΡ€ΠΈ ΠΎΡ†Π΅Π½ΠΊΠ΅ послСопСрационных ΠΏΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»Π΅ΠΉ ΠΎΡ‚ΠΌΠ΅Ρ‡Π΅Π½Π° Ρ€Π°Π·Π½ΠΈΡ†Π° ΠΌΠ΅ΠΆΠ΄Ρƒ 1-ΠΉ ΠΈ 2-ΠΉ Π³Ρ€ΡƒΠΏΠΏΠ°ΠΌΠΈ Π² Π΄Π»ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΠΈ дрСнирования Ρ‚Π°Π·Π° (3,3 ΠΈ 0,9 сут соотвСтствСнно, p = 0,002), срСднСй Π΄Π»ΠΈ- Ρ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΠΈ ΠΊΠ°Ρ‚Π΅Ρ‚Π΅Ρ€ΠΈΠ·Π°Ρ†ΠΈΠΈ (11,2 ΠΈ 5,2 сут соотвСтствСнно, p = 0,0003) ΠΈ Π΄Π»ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΠΈ госпитализации (15,1 ΠΈ 6,5 сут соотвСтствСнно, p = 0,0008).Π—Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅. ΠŸΡ€ΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΏΡ€ΠΈΠ½Ρ†ΠΈΠΏΠΎΠ² ускорСнной ΠΏΡ€ΠΎΠ³Ρ€Π°ΠΌΠΌΡ‹ ΠΏΠ΅Ρ€ΠΈΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ вСдСния ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² (fast track) ΠΏΡ€ΠΈ Π»Π΅Ρ‡Π΅Π½ΠΈΠΈ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… Π ΠŸΠ– Π½Π΅ влияСт Π½Π° частоту ΠΈΠ½Ρ‚Ρ€Π°- ΠΈ послСопСрационных ослоТнСний, ΠΎΠ΄Π½Π°ΠΊΠΎ ΠΏΠΎΡ‚Π΅Π½Ρ†ΠΈΠ°Π»ΡŒΠ½ΠΎ экономичСски Π±ΠΎΠ»Π΅Π΅ цСлСсообразно ΠΏΡ€Π΅ΠΆΠ΄Π΅ всСго Π·Π° счСт ΡƒΠΌΠ΅Π½ΡŒΡˆΠ΅Π½ΠΈΡ срока нахоТдСния больного Π² стационарС

    ΠžΡ‚Π²Π΅Ρ‚ Π½Π° Ρ€Π΅Ρ†Π΅Π½Π·ΠΈΡŽ ΠΊ ΡΡ‚Π°Ρ‚ΡŒΠ΅ "Π Π°Π½Π½Π΅Π΅ ΡƒΠ΄Π°Π»Π΅Π½ΠΈΠ΅ ΡƒΡ€Π΅Ρ‚Ρ€Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ ΠΊΠ°Ρ‚Π΅Ρ‚Π΅Ρ€Π° послС экстрапСритонСоскопичСской Ρ€Π°Π΄ΠΈΠΊΠ°Π»ΡŒΠ½ΠΎΠΉ простатэктомии"

    Get PDF
    .Β Β Π“Π»ΡƒΠ±ΠΎΠΊΠΎΡƒΠ²Π°ΠΆΠ°Π΅ΠΌΡ‹Π΅ ΠΊΠΎΠ»Π»Π΅Π³ΠΈ!Β Β Β Β Β Β Β Β Β Β Β Β ΠœΡ‹ ΡΠΎΠ²Π΅Ρ€ΡˆΠ΅Π½Π½ΠΎ согласны, Ρ‡Ρ‚ΠΎ отсутствиС ΡΡ€Π°Π²Π½ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΊΠΎΠ³ΠΎΡ€Ρ‚Ρ‹ – Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ сущСствСнный нСдостаток исслСдования, ΠΎΠ΄Π½Π°ΠΊΠΎ сравнСниС с Π³Ρ€ΡƒΠΏΠΏΠΎΠΉ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с Π±ΠΎΠ»Π΅Π΅ ΠΏΠΎΠ·Π΄Π½ΠΈΠΌ ΡƒΠ΄Π°Π»Π΅Π½ΠΈΠ΅ΠΌ ΠΊΠ°Ρ‚Π΅Ρ‚Π΅Ρ€Π° Π½Π΅ ΠΏΡ€ΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΠΏΠΎ ΠΏΡ€ΠΈΡ‡ΠΈΠ½Π΅ сущСствСнной нСоднородности Π³Ρ€ΡƒΠΏΠΏ ΠΏΠΎ ΠΏΡ€ΠΈΡ‡ΠΈΠ½Π΅ Ρ€Π°Π·Π½ΠΎΠΉ Ρ‚Π΅Ρ…Π½ΠΈΠΊΠΈ (Π² послСднСм случаС Π±ΠΎΠ»ΡŒΠ½Ρ‹Π΅ ΠΎΠΏΠ΅Ρ€ΠΈΡ€ΠΎΠ²Π°Π»ΠΈΡΡŒ Π² основном Ρ‡Ρ€Π΅Π·Π±Ρ€ΡŽΡˆΠΈΠ½Π½ΠΎ) ΠΈ Ρ€Π°Π·Π½Ρ‹ΠΌ онкологичСским показатСлям (Π±ΠΎΠ»Π΅Π΅ высокая стадия, низкая Π΄ΠΈΡ„Ρ„Π΅Ρ€Π΅Π½Ρ†ΠΈΡ€ΠΎΠ²ΠΊΠ° ΠΈ Ρ‚.ΠΏ.).Β Β Β Β Β Β Β Β Β Β Π”Π΅ΠΉΡΡ‚Π²ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎ, патоморфологичСскиС ΠΈ Ρ€Π°Π½Π½ΠΈΠ΅ онкологичСскиС Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ лСчСния Π½Π΅ являлись основными ΠΈ ΠΏΡ€ΠΈΠ²Π΅Π΄Π΅Π½Ρ‹ ΠΎΠ½ΠΈ Π² ΡΡ‚Π°Ρ‚ΡŒΠ΅ для отобраТСния Ρ‚ΠΎΠ³ΠΎ, Ρ‡Ρ‚ΠΎ Π½Π΅ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Π΅ тСхничСскиС ΠΌΠΎΠΌΠ΅Π½Ρ‚Ρ‹ (Π½Π°ΠΏΡ€ΠΈΠΌΠ΅Ρ€, сохранСниС шСйки ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ пузыря, нСрвосбСрСТСниС ΠΈΒ ΠΏΡ€ΠΎΡ‡Π΅Π΅) ΠΌΠΎΠ³ΡƒΡ‚ ΠΎΠΊΠ°Π·Π°Ρ‚ΡŒ влияниС Π½Π° Ρ„ΡƒΠ½ΠΊΡ†ΠΈΠΎΠ½Π°Π»ΡŒΠ½Ρ‹Π΅ (Π² Ρ‚ΠΎΠΌ числС Ρ„ΡƒΠ½ΠΊΡ†ΠΈΡŽ Π²Π΅Π·ΠΈΠΊΠΎΡƒΡ€Π΅Ρ‚Ρ€Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ анастомоза послС удалСния ΡƒΡ€Π΅Ρ‚Ρ€Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ ΠΊΠ°Ρ‚Π΅Ρ‚Π΅Ρ€Π°) ΠΈ онкологичСскиС Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ (Ρ€Π°ΡΠΏΡ€ΠΎΡΡ‚Ρ€Π°Π½Π΅Π½Π½ΠΎΡΡ‚ΡŒ, состояниС хирургичСского края, ΠΈ Ρ‚.ΠΏ.).Β Β Β Β Β Β Β Β ΠšΠ°ΡΠ°Ρ‚Π΅Π»ΡŒΠ½ΠΎ послСопСрационных ослоТнСний, ΠΏΠΎΡ‚Π΅Π½Ρ†ΠΈΠ°Π»ΡŒΠ½ΠΎ связанныС с Ρ€Π°Π½Π½ΠΈΠΌ ΡƒΠ΄Π°Π»Π΅Π½ΠΈΠ΅ΠΌ УК ΠΎΡ‚ΠΌΠ΅Ρ‡Π΅Π½Ρ‹ Ρƒ 5 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² (17,9%), Ρ‡Ρ‚ΠΎ соотвСтствуСт Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Π°ΠΌ исслСдований ECaRemAΒ (11%) ΠΈΒ RiprecaΒ (13,9%)

    Π Π°Π½Π½Π΅Π΅ ΡƒΠ΄Π°Π»Π΅Π½ΠΈΠ΅ ΡƒΡ€Π΅Ρ‚Ρ€Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ ΠΊΠ°Ρ‚Π΅Ρ‚Π΅Ρ€Π° послС экстрапСритонСоскопичСской Ρ€Π°Π΄ΠΈΠΊΠ°Π»ΡŒΠ½ΠΎΠΉ простатэктомии

    Get PDF
    Background. Extraperitoneal radical prostatectomy (RP) in patients with prostate cancer is useful when there are no oncological indications to lymph node dissection (e.g. in low and intermediate-low risk of the disease), and allows to perform precise anastomosis and facilitates the early postoperative period. However, even minimally invasive approach does not avoid such factors as a urinary catheter that may disturb patients.Objective. We assessed the possibility to remove the urinary catheter as early as possible.Materials and methods. 28 patients with low (n = 22) and low-intermediate (n = 6) prostate cancer risk (according to NCCN (National Comprehensive Cancer Network) criteria) underwent an extraperitoneal laparoscopic RP from March 2017 to November 2018. All operations were performed by the same surgeon (A. Nosov). The inclusion criteria were the following: localized prostate cancer, prostate specific antigen (PSA) <10 ng/ml, ISUP group 1–2, life expectancy of more than 10 years and preoperative patient’s counseling (awareness about early catheter removal and discharge). All patients were continent before surgery. During surgery, the prostate and seminal vesicles were removed extraperitoneally without peritoneal cavity opening and conversion. Bladder neck sparing was performed in all cases but nerve-vascular bundles were spared according to indication (preoperative International Index of Erectile Function (IIEF), oncological reasons). Vesicourethral anastomosis was performed by two V-Loc circular sutures. No drainage tubes were inserted to control bleeding/urinary leakage. A urinary catheter Foley 20 Fr was inserted into the bladder after anastomosis completion. No other urinary drainage (suprapubic tubes, etc) was used. Anastomosis resistance and completeness were checked at the end of surgery by filling the bladder with 150 ml of saline through the catheter. Except for cases with macroscopic hematuria, urinary catheters were removed on the 1st postoperative day’s morning (<24 hours) with an active followup (daily voiding assessment, pelvic ultrasound and postvoided residual volume assessment) on Day 1. Immediately after the catheter removal, alpha-blockers (for urination alleviation) and PDE-5 inhibitors (in patients with neurovascular sparing) were prescribed. All patients were available for a 3-month follow-up. During the follow-up, a monthly combined assessment was performed, including IPSS, QoL, PSA analysis, pelvic ultrasound and urofloumetry.Results. The average patient’s age was 63 years (52–71 years). The median preoperative PSA level was 7.6 ng/ml. The intraoperative technique was unremarkable with no blood transfusion or conversion. All early postoperative complications were classified as minor – grade I, II and IIIa in 2 (7.2 %), 5 (17.8 %) and 1 (3.6 %) patients, respectively. Related to the early catheter removal complications included 1 (3.6 %) patient with urinary leakage (resolved by repeated prolonged urinary catheter insertion) and 4 (14.3 %) with urinary obstruction – resolved by single catheterization (n = 2), percutaneous suprapubic cystostomy (n = 2). No major complications were noticed during the follow-up. Totally, 22 (78.6 %) patients were discharged on the next day after the catheter removal – on the 2nd postoperative day. All discharged patients did not need readmission during the follow-up. Remained 6 (21.4 %) patients stayed at the hospital for 5–18 days. The pathological investigation showed upgrading in 9 (32.1 %) patients with low risk and in 1 (3.6 %) patient with low-intermediate risk. Upstaging to locally advanced forms was noticed in 6 (21.4 %) patients. All patients had the PSA level of <0.2 ng/ml 30–90 days after surgery. Postoperative assessment showed improvement in urinary function and erectile function sparing in selected patients, with no compromising functional results due to the early catheter removal.Conclusion. Despite the common widespread of minimally invasive RP, there is no consensus on the terms of a urinary catheter removal. According to our data, we suggested it might be of some benefit to remove a urinary catheter early in selected and well-informed patients. A thorough vesicourethral anastomosis pursuance, nerve-sparing, bladder neck sparing and Retzius sparing procedure, intraand postoperative assessment is necessary in all cases.Π’Π²Π΅Π΄Π΅Π½ΠΈΠ΅. Π­ΠΊΡΡ‚Ρ€Π°ΠΏΠ΅Ρ€ΠΈΡ‚ΠΎΠ½Π΅Π°Π»ΡŒΠ½Π°Ρ Ρ€Π°Π΄ΠΈΠΊΠ°Π»ΡŒΠ½Π°Ρ простатэктомия (РПЭ) Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с Ρ€Π°ΠΊΠΎΠΌ ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹ ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΡƒΠ΅Ρ‚ΡΡ ΠΏΡ€ΠΈ отсутствии ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΈΠΉ для выполнСния Ρ‚Π°Π·ΠΎΠ²ΠΎΠΉ лимфадСнэктомии, Ρ‚. Π΅. ΠΏΡ€ΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΈ Π½ΠΈΠ·ΠΊΠΎΠ³ΠΎ ΠΈ ΠΏΡ€ΠΎΠΌΠ΅ΠΆΡƒΡ‚ΠΎΡ‡Π½ΠΎΠ½ΠΈΠ·ΠΊΠΎΠ³ΠΎ риска. Минимально ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½Ρ‹Π΅ Ρ‚Π΅Ρ…Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΏΡ€ΠΈ Π΅Π΅ Π²Ρ‹ΠΏΠΎΠ»Π½Π΅Π½ΠΈΠΈ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡŽΡ‚ ΠΎΡΡƒΡ‰Π΅ΡΡ‚Π²ΠΈΡ‚ΡŒ ΠΏΡ€Π΅Ρ†ΠΈΠ·ΠΈΠΎΠ½Π½ΠΎΠ΅ Ρ„ΠΎΡ€ΠΌΠΈΡ€ΠΎΠ²Π°Π½ΠΈΠ΅ Π²Π΅Π·ΠΈΠΊΠΎΡƒΡ€Π΅Ρ‚Ρ€Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ анастомоза ΠΈ Π·Π°Ρ‡Π°ΡΡ‚ΡƒΡŽ ΠΎΠ±Π»Π΅Π³Ρ‡ΠΈΡ‚ΡŒ Ρ‚Π΅Ρ‡Π΅Π½ΠΈΠ΅ Ρ€Π°Π½Π½Π΅Π³ΠΎ послСопСрационного ΠΏΠ΅Ρ€ΠΈΠΎΠ΄Π°. Π’Π΅ΠΌ Π½Π΅ ΠΌΠ΅Π½Π΅Π΅ Π΄Π°ΠΆΠ΅ минимально ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½Ρ‹ΠΉ ΠΏΠΎΠ΄Ρ…ΠΎΠ΄ Π½Π΅ позволяСт ΠΈΠ·Π±Π΅ΠΆΠ°Ρ‚ΡŒ Ρ„Π°ΠΊΡ‚ΠΎΡ€ΠΎΠ², ΡƒΡ…ΡƒΠ΄ΡˆΠ°ΡŽΡ‰ΠΈΡ… качСство ΠΆΠΈΠ·Π½ΠΈ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² Π² послСопСрационном ΠΏΠ΅Ρ€ΠΈΠΎΠ΄Π΅, Ρ‚Π°ΠΊΠΈΡ… ΠΊΠ°ΠΊ ΡƒΡ€Π΅Ρ‚Ρ€Π°Π»ΡŒΠ½Ρ‹ΠΉ ΠΊΠ°Ρ‚Π΅Ρ‚Π΅Ρ€.ЦСль исслСдования – ΠΎΡ†Π΅Π½ΠΊΠ° возмоТности удалСния ΡƒΡ€Π΅Ρ‚Ρ€Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ ΠΊΠ°Ρ‚Π΅Ρ‚Π΅Ρ€Π° Π² максимально Ρ€Π°Π½Π½ΠΈΠ΅ сроки послС выполнСния РПЭ.ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹ ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. Π‘ ΠΌΠ°Ρ€Ρ‚Π° 2017 Π³. ΠΏΠΎ Π½ΠΎΡΠ±Ρ€ΡŒ 2018 Π³. Π² НМИЦ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈΠΌ. Н. Н. ΠŸΠ΅Ρ‚Ρ€ΠΎΠ²Π° 28 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π°ΠΌ с Ρ€Π°ΠΊΠΎΠΌ ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹ Π½ΠΈΠ·ΠΊΠΎΠ³ΠΎ (n = 22) ΠΈ ΠΏΡ€ΠΎΠΌΠ΅ΠΆΡƒΡ‚ΠΎΡ‡Π½ΠΎ-Π½ΠΈΠ·ΠΊΠΎΠ³ΠΎ (n = 6) риска (согласно критСриям NCCN (National Comprehensive Cancer Network)) Π±Ρ‹Π»Π° ΠΏΡ€ΠΎΠ²Π΅Π΄Π΅Π½Π° ΡΠΊΡΡ‚Ρ€Π°ΠΏΠ΅Ρ€ΠΈΡ‚ΠΎΠ½Π΅Π°Π»ΡŒΠ½Π°Ρ лапароскопичСская РПЭ. ВсС ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΈ Π²Ρ‹ΠΏΠΎΠ»Π½Π΅Π½Ρ‹ ΠΎΠ΄Π½ΠΈΠΌ Ρ…ΠΈΡ€ΡƒΡ€Π³ΠΎΠΌ (А. К. Носов). ΠšΡ€ΠΈΡ‚Π΅Ρ€ΠΈΡΠΌΠΈ Π²ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΡ Π² исслСдованиС явились Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½Ρ‹ΠΉ Ρ€Π°ΠΊ ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹, ΡƒΡ€ΠΎΠ²Π΅Π½ΡŒ простатичСского спСцифичСского Π°Π½Ρ‚ΠΈΠ³Π΅Π½Π° (ПБА) <10 Π½Π³ / ΠΌΠ», сумма Π±Π°Π»Π»ΠΎΠ² ΠΏΠΎ шкалС Глисона ≀7, оТидаСмая ΠΏΡ€ΠΎΠ΄ΠΎΠ»ΠΆΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ ΠΆΠΈΠ·Π½ΠΈ Π±ΠΎΠ»Π΅Π΅ 10 Π»Π΅Ρ‚ ΠΈ ΠΏΡ€Π΅Π΄ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΎΠ½Π½ΠΎΠ΅ ΠΊΠΎΠ½ΡΡƒΠ»ΡŒΡ‚ΠΈΡ€ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π° (освСдомлСниС ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π° ΠΎ Ρ€Π°Π½Π½Π΅ΠΌ ΡƒΠ΄Π°Π»Π΅Π½ΠΈΠΈ ΡƒΡ€Π΅Ρ‚Ρ€Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ ΠΊΠ°Ρ‚Π΅Ρ‚Π΅Ρ€Π°). ВсС ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Ρ‹ ΠΏΠ΅Ρ€Π΅Π΄ РПЭ ΠΏΠΎΠ»Π½ΠΎΡΡ‚ΡŒΡŽ ΡƒΠ΄Π΅Ρ€ΠΆΠΈΠ²Π°Π»ΠΈ ΠΌΠΎΡ‡Ρƒ. Π’ Ρ…ΠΎΠ΄Π΅ Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π²Π° ΠΏΡ€ΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ ΡΠΊΡΡ‚Ρ€Π°ΠΏΠ΅Ρ€ΠΈΡ‚ΠΎΠ½Π΅Π°Π»ΡŒΠ½ΠΎΠ΅ ΡƒΠ΄Π°Π»Π΅Π½ΠΈΠ΅ ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹, сСмСнных ΠΏΡƒΠ·Ρ‹Ρ€ΡŒΠΊΠΎΠ², Π²ΠΎ всСх случаях выполняли сохранСниС шСйки ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ пузыря ΠΈ ΠΏΡ€ΠΈ Π½Π°Π»ΠΈΡ‡ΠΈΠΈ ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΈΠΉ (Π½ΠΎΡ€ΠΌΠ°Π»ΡŒΠ½Π°Ρ прСдопСрационная функция ΠΏΠΎ ΠΎΡ†Π΅Π½ΠΊΠ΅ опросника ΠœΠ΅ΠΆΠ΄ΡƒΠ½Π°Ρ€ΠΎΠ΄Π½ΠΎΠ³ΠΎ индСкса ΡΡ€Π΅ΠΊΡ‚ΠΈΠ»ΡŒΠ½ΠΎΠΉ Ρ„ΡƒΠ½ΠΊΡ†ΠΈΠΈ (МИЭЀ-5), подходящиС онкологичСскиС ΠΊΡ€ΠΈΡ‚Π΅Ρ€ΠΈΠΈ) нСрвосбСрСТСниС. Π€ΠΎΡ€ΠΌΠΈΡ€ΠΎΠ²Π°Π½ΠΈΠ΅ Π²Π΅Π·ΠΈΠΊΠΎΡƒΡ€Π΅Ρ‚Ρ€Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ анастомоза, Ρ‚Ρ‰Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ ΠΈ ΠΏΡ€Π΅Ρ†ΠΈΠ·ΠΈΠΎΠ½Π½ΠΎΡΡ‚ΡŒ ΠΊΠΎΡ‚ΠΎΡ€ΠΎΠ³ΠΎ ΡΡ‡ΠΈΡ‚Π°Π»ΠΈΡΡŒ ΠΊΠ»ΡŽΡ‡Π΅Π²Ρ‹ΠΌ ΠΌΠΎΠΌΠ΅Π½Ρ‚ΠΎΠΌ Π² возмоТности Ρ€Π°Π½Π½Π΅Π³ΠΎ удалСния ΡƒΡ€Π΅Ρ‚Ρ€Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ ΠΊΠ°Ρ‚Π΅Ρ‚Π΅Ρ€Π°, осущСствляли с ΠΏΠΎΠΌΠΎΡ‰ΡŒΡŽ циркулярного шва нитями V-Loc. ПослС формирования анастомоза Π΅Π³ΠΎ Π³Π΅Ρ€ΠΌΠ΅Ρ‚ΠΈΡ‡Π½ΠΎΡΡ‚ΡŒ ΠΎΡ†Π΅Π½ΠΈΠ²Π°Π»ΠΈ Π²Π²Π΅Π΄Π΅Π½ΠΈΠ΅ΠΌ ΠΏΠΎ устанавливаСмому ΡƒΡ€Π΅Ρ‚Ρ€Π°Π»ΡŒΠ½ΠΎΠΌΡƒ ΠΊΠ°Ρ‚Π΅Ρ‚Π΅Ρ€Ρƒ ЀолСя β„– 20 Ch 150 ΠΌΠ» физиологичСского раствора. Π”Ρ€ΡƒΠ³ΠΈΠ΅ ΠΌΠΎΡ‡Π΅Π²Ρ‹Π΅ / страховыС Π΄Ρ€Π΅Π½Π°ΠΆΠΈ Π½Π΅ устанавливали. Π—Π° ΠΈΡΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅ΠΌ случаСв ΠΌΠ°ΠΊΡ€ΠΎΠ³Π΅ΠΌΠ°Ρ‚ΡƒΡ€ΠΈΠΈ ΡƒΡ€Π΅Ρ‚Ρ€Π°Π»ΡŒΠ½Ρ‹ΠΉ ΠΊΠ°Ρ‚Π΅Ρ‚Π΅Ρ€ удаляли Π½Π° 1‑С сутки послСопСрационного ΠΏΠ΅Ρ€ΠΈΠΎΠ΄Π° (<24 Ρ‡) с ΠΏΠΎΡΠ»Π΅Π΄ΡƒΡŽΡ‰ΠΈΠΌ Π°ΠΊΡ‚ΠΈΠ²Π½Ρ‹ΠΌ наблюдСниСм Π·Π° ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠΌ – ΡΡƒΠ±ΡŠΠ΅ΠΊΡ‚ΠΈΠ²Π½Π°Ρ ΠΈ ΠΎΠ±ΡŠΠ΅ΠΊΡ‚ΠΈΠ²Π½Π°Ρ ΠΎΡ†Π΅Π½ΠΊΠ° мочСиспускания (Π΄Π½Π΅Π²Π½ΠΈΠΊ мочСиспусканий, ΡƒΠ»ΡŒΡ‚Ρ€Π°Π·Π²ΡƒΠΊΠΎΠ²ΠΎΠ΅ ΠΎΠΏΡ€Π΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ остаточной ΠΌΠΎΡ‡ΠΈ). Π‘Ρ€Π°Π·Ρƒ послС удалСния ΡƒΡ€Π΅Ρ‚Ρ€Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ ΠΊΠ°Ρ‚Π΅Ρ‚Π΅Ρ€Π° Π½Π°Π·Π½Π°Ρ‡Π°Π»ΠΈ ΠΈΠ½Π³ΠΈΠ±ΠΈΡ‚ΠΎΡ€Ρ‹ Π€Π”Π­-5 (ΠΏΡ€ΠΈ Π²Ρ‹ΠΏΠΎΠ»Π½Π΅Π½ΠΈΠΈ Π½Π΅Ρ€Π²ΠΎΡΠ±Π΅Ρ€Π΅Π³Π°ΡŽΡ‰Π΅ΠΉ РПЭ) ΠΈ Ξ±-Π°Π΄Ρ€Π΅Π½ΠΎΠ±Π»ΠΎΠΊΠ°Ρ‚ΠΎΡ€Ρ‹. ВсС ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Ρ‹ Π±Ρ‹Π»ΠΈ доступны для 3‑мСсячного наблюдСния. Π’ Ρ‚Π΅Ρ‡Π΅Π½ΠΈΠ΅ наблюдСния ΠΏΡ€ΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ Π΅ΠΆΠ΅ΠΌΠ΅ΡΡΡ‡Π½ΡƒΡŽ ΠΎΡ†Π΅Π½ΠΊΡƒ состояния: Π°Π½Π°Π»ΠΈΠ· опросников IPSS, QoL, уровня ПБА, ΠΎΡ†Π΅Π½ΠΊΡƒ остаточной ΠΌΠΎΡ‡ΠΈ, ΡƒΡ€ΠΎΡ„Π»ΠΎΡƒΠΌΠ΅Ρ‚Ρ€ΠΈΡŽ.Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. Π‘Ρ€Π΅Π΄Π½ΠΈΠΉ возраст ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² составил 63 Π³ΠΎΠ΄Π° (52–71 Π³ΠΎΠ΄). Π‘Ρ€Π΅Π΄Π½ΠΈΠΉ ΡƒΡ€ΠΎΠ²Π΅Π½ΡŒ ПБА ΠΏΠ΅Ρ€Π΅Π΄ ΠΏΡ€ΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ΠΌ РПЭ – 7,6 Π½Π³ / ΠΌΠ». Π’ΠΎ врСмя ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΈ Π½ΠΈ Ρƒ ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π° Π½Π΅ ΠΏΠΎΡ‚Ρ€Π΅Π±ΠΎΠ²Π°Π»ΠΎΡΡŒ выполнСния гСмотрансфузии ΠΈΠ»ΠΈ конвСрсии. Рутинная цистография ΠΏΠ΅Ρ€Π΅Π΄ ΡƒΠ΄Π°Π»Π΅Π½ΠΈΠ΅ΠΌ ΡƒΡ€Π΅Ρ‚Ρ€Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ ΠΊΠ°Ρ‚Π΅Ρ‚Π΅Ρ€Π° Π½Π΅ Π²Ρ‹ΠΏΠΎΠ»Π½ΡΠ»Π°ΡΡŒ. ВсС ослоТнСния Ρ€Π°Π½Π½Π΅Π³ΠΎ послСопСрационного ΠΏΠ΅Ρ€ΠΈΠΎΠ΄Π° отнСсСны ΠΊ Π½Π΅Π·Π½Π°Ρ‡ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹ΠΌ I, II ΠΈ IIIa стСпСням соотвСтствСнно Ρƒ 2 (7,2 %), 5 (17,8 %) ΠΈ 1 (3,6 %) ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π°. БвязанныС с Ρ€Π°Π½Π½ΠΈΠΌ ΡƒΠ΄Π°Π»Π΅Π½ΠΈΠ΅ΠΌ ΡƒΡ€Π΅Ρ‚Ρ€Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ ΠΊΠ°Ρ‚Π΅Ρ‚Π΅Ρ€Π° ослоТнСния Π²ΠΊΠ»ΡŽΡ‡Π°Π»ΠΈ Π·Π°Ρ‚Π΅ΠΊ ΠΌΠΎΡ‡ΠΈ ΠΈΠ· Π·ΠΎΠ½Ρ‹ Π²Π΅Π·ΠΈΠΊΠΎΡƒΡ€Π΅Ρ‚Ρ€Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ анастомоза (Ρƒ 1 (3,6 %) ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π° Ρ€Π°Π·Ρ€Π΅ΡˆΠ΅Π½ΠΎ ΠΏΠΎΠ²Ρ‚ΠΎΡ€Π½ΠΎΠΉ установкой ΠΊΠ°Ρ‚Π΅Ρ‚Π΅Ρ€Π° ΠΈ ΠΏΡ€ΠΎΠ»ΠΎΠ½Π³ΠΈΡ€ΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΊΠ°Ρ‚Π΅Ρ‚Π΅Ρ€ΠΈΠ·Π°Ρ†ΠΈΠ΅ΠΉ) ΠΈ ΠΎΠ±ΡΡ‚Ρ€ΡƒΠΊΡ†ΠΈΡŽ мочСиспускания (Ρƒ 4 (14,3 %) ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ², ΠΈΠ· Π½ΠΈΡ… 2 Π²Ρ‹ΠΏΠΎΠ»Π½Π΅Π½Π° повторная катСтСризация ΠΈ 2 – троакарная эпицистостомия). На ΡΠ»Π΅Π΄ΡƒΡŽΡ‰ΠΈΠΉ дСнь послС удалСния ΠΊΠ°Ρ‚Π΅Ρ‚Π΅Ρ€Π° (2‑й послСопСрационный дСнь) Π±Ρ‹Π»ΠΈ выписаны 22 (78,6 %) ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π°. ΠŸΠΎΠ²Ρ‚ΠΎΡ€Π½Ρ‹Ρ… госпитализаций Ρƒ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… этой Π³Ρ€ΡƒΠΏΠΏΡ‹ Π½Π΅ ΠΏΠΎΡ‚Ρ€Π΅Π±ΠΎΠ²Π°Π»ΠΎΡΡŒ. Π£ 6 (21,4 %) ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² ΠΏΡ€ΠΎΠ΄ΠΎΠ»ΠΆΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ госпитализации составила 5–18 Π΄Π½Π΅ΠΉ. ΠŸΡ€Π΅Π΄ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΎΠ½Π½ΠΎΠ΅ Π·Π°Π½ΠΈΠΆΠ΅Π½ΠΈΠ΅ стСпСни Π΄ΠΈΡ„Ρ„Π΅Ρ€Π΅Π½Ρ†ΠΈΡ€ΠΎΠ²ΠΊΠΈ ΠΎΡ‚ΠΌΠ΅Ρ‡Π΅Π½ΠΎ Ρƒ 9 (32,1 %) ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² ΠΈΠ· Π³Ρ€ΡƒΠΏΠΏΡ‹ Π½ΠΈΠ·ΠΊΠΎΠ³ΠΎ риска ΠΈ Ρƒ 1 (3,6 %) больного ΠΈΠ· Π³Ρ€ΡƒΠΏΠΏΡ‹ ΠΏΡ€ΠΎΠΌΠ΅ΠΆΡƒΡ‚ΠΎΡ‡Π½ΠΎ-Π½ΠΈΠ·ΠΊΠΎΠ³ΠΎ. Π’ 6 случаях ΠΈΠ·Π½Π°Ρ‡Π°Π»ΡŒΠ½ΠΎ Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½Ρ‹ΠΉ процСсс патоморфологичСски ΠΎΡ†Π΅Π½Π΅Π½ ΠΊΠ°ΠΊ мСстно-распространСнный с ΠΈΠ½Π²Π°Π·ΠΈΠ΅ΠΉ Π² сСмСнныС ΠΏΡƒΠ·Ρ‹Ρ€ΡŒΠΊΠΈ (n = 2) ΠΈΠ»ΠΈ с экстропростатичСским распространСниСм (n = 4). ВсС ΠΏΡ€ΠΎΠΎΠΏΠ΅Ρ€ΠΈΡ€ΠΎΠ²Π°Π½Π½Ρ‹Π΅ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Ρ‹ ΠΈΠΌΠ΅Π»ΠΈ ΡƒΡ€ΠΎΠ²Π΅Π½ΡŒ ПБА <0,2 Π½Π³ / ΠΌΠ» Π² Ρ‚Π΅Ρ‡Π΅Π½ΠΈΠ΅ 90 Π΄Π½Π΅ΠΉ послС ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΈ. ΠŸΠΎΡΠ»Π΅ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΎΠ½Π½Π°Ρ ΠΎΡ†Π΅Π½ΠΊΠ° ΠΏΠΎΠΊΠ°Π·Π°Π»Π° ΡƒΠ»ΡƒΡ‡ΡˆΠ΅Π½ΠΈΠ΅ Ρ„ΡƒΠ½ΠΊΡ†ΠΈΠΈ мочСиспускания ΠΈ Ρƒ ΠΎΡ‚Π΄Π΅Π»ΡŒΠ½Ρ‹Ρ… ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² сохранСниС ΡΡ€Π΅ΠΊΡ‚ΠΈΠ»ΡŒΠ½ΠΎΠΉ Ρ„ΡƒΠ½ΠΊΡ†ΠΈΠΈ послС выполнСния РПЭ с послСопСрационным Π²Π΅Π΄Π΅Π½ΠΈΠ΅ΠΌ ΠΏΠΎ ΠΏΡ€Π΅Π΄Π»ΠΎΠΆΠ΅Π½Π½ΠΎΠΉ ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΈΠΊΠ΅.Π—Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅. НСсмотря Π½Π° Ρ€Π°Π·Π²ΠΈΡ‚ΠΈΠ΅ хирургичСской Ρ‚Π΅Ρ…Π½ΠΈΠΊΠΈ ΠΈ ΡˆΠΈΡ€ΠΎΠΊΠΎΠ΅ распространСниС минимально ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½ΠΎΠ³ΠΎ ΠΏΠΎΠ΄Ρ…ΠΎΠ΄Π° Π² хирургичСском Π»Π΅Ρ‡Π΅Π½ΠΈΠΈ Ρ€Π°ΠΊΠ° ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹, Π΅Π΄ΠΈΠ½ΠΎΠ³ΠΎ мнСния ΠΎ сроках удалСния ΡƒΡ€Π΅Ρ‚Ρ€Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ ΠΊΠ°Ρ‚Π΅Ρ‚Π΅Ρ€Π° Π½Π΅Ρ‚. Наши Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΈ, Ρ‡Ρ‚ΠΎ ΠΏΡ€ΠΈ Π°Π΄Π΅ΠΊΠ²Π°Ρ‚Π½ΠΎΠΌ Ρ„ΠΎΡ€ΠΌΠΈΡ€ΠΎΠ²Π°Π½ΠΈΠΈ Π²Π΅Π·ΠΈΠΊΠΎΡƒΡ€Π΅Ρ‚Ρ€Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ анастомоза с сохранСниСм шСйки ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ пузыря, Ρ€Π΅Ρ‚Ρ†ΠΈΠ΅Π²ΠΎΠ³ΠΎ пространства, ΠΏΡ€ΠΈ Π²Ρ‹ΠΏΠΎΠ»Π½Π΅Π½ΠΈΠΈ нСрвосбСрСТСния, Ρ‚Ρ‰Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΌ ΠΏΡ€Π΅Ρ†ΠΈΠ·ΠΈΠΎΠ½Π½ΠΎΠΌ Ρ„ΠΎΡ€ΠΌΠΈΡ€ΠΎΠ²Π°Π½ΠΈΠΈ анастомоза, ΠΎΠ±ΡΠ·Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΌ ΠΈΠ½Ρ‚Ρ€Π°ΠΈ послСопСрационном ΠΊΠΎΠ½Ρ‚Ρ€ΠΎΠ»Π΅ ΠΈ Ρƒ ΠΏΡ€ΠΎΠΈΠ½Ρ„ΠΎΡ€ΠΌΠΈΡ€ΠΎΠ²Π°Π½Π½Ρ‹Ρ… ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎ Ρ€Π°Π½Π½Π΅Π΅ ΡƒΠ΄Π°Π»Π΅Π½ΠΈΠ΅ ΠΊΠ°Ρ‚Π΅Ρ‚Π΅Ρ€Π°

    ΠŸΡ€ΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ стрСптокиназы ΠΏΡ€ΠΈ ΡΠ²Π΅Ρ€Π½ΡƒΠ²ΡˆΠ΅ΠΌΡΡ гСмотораксС

    Get PDF
    Pleural effusion in patients with clotting haemothorax is characterized by high coagulant potential and low fibrinolytic activity. Streptokinase is an effective drug for pharmacological lung decortication in patients with high pleural concentration of plasminogen.Intrapleural administration of streptokinase-activated fresh frozen plasma increased efficacy of conservative therapy and provided better outcome in clotting haemothorax.Π£ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… ΡΠ²Π΅Ρ€Π½ΡƒΠ²ΡˆΠΈΠΌΡΡ гСмотораксом (Π‘Π“) Π² ΠΏΠ»Π΅Π²Ρ€Π°Π»ΡŒΠ½ΠΎΠΌ экссудатС ΠΏΡ€ΠΈ сохранСнном коагуляционном ΠΏΠΎΡ‚Π΅Π½Ρ†ΠΈΠ°Π»Π΅ Π·Π½Π°Ρ‡ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎ ΡƒΠ³Π½Π΅Ρ‚Π΅Π½ Ρ„ΠΈΠ±Ρ€ΠΈΠ½ΠΎΠ»ΠΈΠ·, Ρ‡Ρ‚ΠΎ способствуСт Ρ„ΠΈΠ±Ρ€ΠΈΠ½ΠΎΠΎΠ±Ρ€Π°Π·ΠΎΠ²Π°Π½ΠΈΡŽ Π² ΠΏΠ»Π΅Π²Ρ€Π°Π»ΡŒΠ½ΠΎΠΉ полости. Π’Π½ΡƒΡ‚Ρ€ΠΈΠΏΠ»Π΅Π²Ρ€Π°Π»ΡŒΠ½ΠΎΠ΅ Π²Π²Π΅Π΄Π΅Π½ΠΈΠ΅ ΠΏΡ€Π΅ΠΏΠ°Ρ€Π°Ρ‚ΠΎΠ² стрСптокиназы являСтся эффСктивным способом ΠΌΠ΅Π΄ΠΈΠΊΠ°ΠΌΠ΅Π½Ρ‚ΠΎΠ·Π½ΠΎΠΉ Π΄Π΅ΠΊΠΎΡ€Ρ‚ΠΈΠΊΠ°Ρ†ΠΈΠΈ Π»Π΅Π³ΠΊΠΎΠ³ΠΎ Ρƒ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… ΡΠ²Π΅Ρ€Π½ΡƒΠ²ΡˆΠΈΠΌΡΡ гСмотораксом с высоким содСрТаниСм ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π° Π² ΠΏΠ»Π΅Π²Ρ€Π°Π»ΡŒΠ½ΠΎΠΉ полости. Π’Π½ΡƒΡ‚Ρ€ΠΈΠΏΠ»Π΅Π²Ρ€Π°Π»ΡŒΠ½ΠΎΠ΅ ΠΏΡ€ΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ свСТСзамороТСнной ΠΏΠ»Π°Π·ΠΌΡ‹, Π°ΠΊΡ‚ΠΈΠ²ΠΈΡ€ΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΏΡ€Π΅ΠΏΠ°Ρ€Π°Ρ‚Π°ΠΌΠΈ стрСптокиназы, позволяСт Π·Π½Π°Ρ‡ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎ ΠΏΠΎΠ²Ρ‹ΡΠΈΡ‚ΡŒ ΡΡ„Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ консСрвативной Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ Ρƒ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… Π‘Π“ ΠΈ ΡƒΠ»ΡƒΡ‡ΡˆΠΈΡ‚ΡŒ исходы заболСвания

    Evaluation of Effectiveness of Yersinia pestis Molecular Diagnostics in the Field Material from Sarydzhas Focus in Kyrgyzstan

    Get PDF
    Objective of the study is to assess the effectiveness of the methods for molecular diagnostics and identification of Yersinia pestis strains in the field material obtained from Sarydzhas high-mountain focus in Kyrgyz Republic. Materials and methods. Investigated were the samples of the field material, isolated in 2016 in Sarydzhas high-mountain plague focus, using conventional methods of laboratory diagnostics and PCR with hybridization-fluorescent and electrophoretic registration of results. Results and conclusions. It is demonstrated that in a number of cases molecular-genetic method has a higher resolution as compared to conventional methods of laboratory diagnostics of plague. It proves the necessity of wider usage of molecular-diagnostic methods in epizootiological monitoring of plague in natural foci in Kyrgyz Republic

    ΠžΠ‘ΠΠžΠ’Π« Π˜Π‘ΠŸΠžΠ›Π¬Π—ΠžΠ’ΠΠΠ˜Π― ΠœΠΠ“ΠΠ˜Π’ΠΠž-Π Π•Π—ΠžΠΠΠΠ‘ΠΠžΠ™ Π’ΠžΠœΠžΠ“Π ΠΠ€Π˜Π˜ ПРИ Π ΠΠšΠ• ΠŸΠ Π•Π”Π‘Π’ΠΠ’Π•Π›Π¬ΠΠžΠ™ Π–Π•Π›Π•Π—Π«

    Get PDF
    The article discusses the possibilities of basic MRI techniques in primary prostate cancer diagnosis based on the MRI characteristics of anatomical and histological features of prostate. The assesment of prostate cancer distribution, stratification of risk for progression and the decision for treatment tactics, in accompanying of remedial actions, in treatment effectiveness monitoring and in early detection of relapses is discussed.На основС спСцифики отобраТСния ΠΏΡ€ΠΈ МРВ Π°Π½Π°Ρ‚ΠΎΠΌΠΎ-гистологичСских особСнностСй строСния ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹, Π° Ρ‚Π°ΠΊΠΆΠ΅ физичСских ΠΏΡ€ΠΈΠ½Ρ†ΠΈΠΏΠΎΠ² получСния ΡΠΎΠΎΡ‚Π²Π΅Ρ‚ΡΡ‚Π²ΡƒΡŽΡ‰ΠΈΡ… ΠΈΠ·ΠΎΠ±Ρ€Π°ΠΆΠ΅Π½ΠΈΠΉ прСдставлСно обсуТдСниС возмоТностСй основных ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΈΠΊ МРВ Π² ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½ΠΎΠΉ диагностикС Ρ€Π°ΠΊΠ° простаты, Π² ΠΎΡ†Π΅Π½ΠΊΠ΅ Π΅Π³ΠΎ распространСния, Π² стратификации риска прогрСссирования ΠΈ ΠΎΠΏΡ€Π΅Π΄Π΅Π»Π΅Π½ΠΈΠΈ Π»Π΅Ρ‡Π΅Π±Π½ΠΎΠΉ Ρ‚Π°ΠΊΡ‚ΠΈΠΊΠΈ, ΠΏΡ€ΠΈ сопровоТдСнии Π»Π΅Ρ‡Π΅Π±Π½Ρ‹Ρ… мСроприятий, Π² ΠΊΠΎΠ½Ρ‚Ρ€ΠΎΠ»Π΅ ΠΈΡ… эффСктивности, Π° Ρ‚Π°ΠΊΠΆΠ΅ Π² Ρ€Π°Π½Π½Π΅ΠΌ выявлСнии Ρ€Π΅Ρ†ΠΈΠ΄ΠΈΠ²ΠΎΠ²
    • …
    corecore